Interactions between oral anticoagulants and therapies of
COVID-19
Stroke prevention with oral anticoagulants (OACs), including vitamin K
antagonist (warfarin) and non-vitamin K antagonist OACs (NOACs), is the
cornerstone for the managements of AF. Before initiations of OACs for AF
patients infected with COVID-19, it is necessary to check platelet
counts, coagulation profiles (e.g. prothrombin time and activated
partial thromboplastin time), renal s and liver functions which are
probably affected with severe infections. Importantly, these parameters
should be monitored and followed up closely during the disease course,
and the dosages of OACs should be adjusted when indicated.